12th Annual HealthTech Investment Forum

Navignostics is a precision oncology diagnostics company pioneering the use of spatial single-cell proteomics to transform cancer diagnostics and treatment selection. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, Navignostics combines highly multiplex tumor imaging with advanced data analytics to guide clinicians in identifying the most effective, personalized therapies for each cancer patient. Navignostics’ test delivers detailed insights into tumor and immune cell composition from a single tissue section, providing a report that supports both individualized treatment decisions for patients and the development of novel targeted therapies. The company collaborates with leading clinics and pharmaceutical partners, improving clinical trial success and patient outcomes by matching the right patients with the right therapies.

Globally, 11 million patients die due to severe infections annually. This tragic statistic is largely due to the limitations of current diagnostic methods, which are often slow and lack both sensitivity and comprehensive pathogen coverage. The consequence of inadequate or untargeted therapy is a rise in preventable deaths and impairments, significant subsequent healthcare costs, and increasing antibiotic resistance. Noscendo addresses this critical need with DISQVER®, a revolutionary diagnostic platform. DISQVER® leverages next-generation sequencing (NGS) of cell-free DNA, isolated from blood samples, to precisely identify 16.000 microbes and parasites. A key feature of the platform is its ability to correct for contamination introduced during the wet lab process, ensuring highly accurate results.

QuantHealth's technology predicts how any patient will respond to any treatment, supporting smarter trial planning, indication selection, drug in-licensing, and portfolio optimization. By generating synthetic evidence across all clinical phases, QuantHealth is shaping the future of healthcare.

We bridge the gap between preclinical and clinical neuroscience by evaluating the performance of neurology therapeutic assets on the most clinically relevant in vitro platform available. Tessara leads the world with our RealBrain drug screening platform, combining reproducibility and scalability with human physiological relevance in 3D in vitro models. RealBrain models feature functional neural networks and closely mimic human neurophysiology. The RealBrain microtissues are cultured from neural precursor cells mixed with biomaterials in a one-step casting process that mitigates the typical limitations of in vitro technologies. Automation, developed through partnerships with robotics leaders, enables consistent, rapid production of microtissues with minimal variation. Furthermore, AI algorithms transform the neural architecture into digital 3D maps for automatic detection and quantification of neural network architecture. This allows precise assessment of drug effects on various cell populations and neural connectivity. Unique in its capability for high-throughput, high-content analysis, the RealBrain platform combines sophisticated biology with user-friendly handling, to accelerate drug discovery and predict which drug candidates are more likely to be efficacious in human clinical trials.

The Corbotics Echo Robot automates the Trans Thoracic Echocardiogram using patented AI/ML and robotics. Our disruptive device will not need any sonographer or cardiologist anymore for the acquisition of the cardiac ultrasound images and will outperform the current standard of care in scalability, cost effectiveness and standardization with non-inferior image quality compared to seasoned sonographers of which shortages are rapidly growing in many western countries. We have clinically validated our device showing non-inferiority and great patient comfort and we are currently finalizing MDR and FDA submissions. We have a pipeline of commercial leads, a clear commercial strategy and are solidly financed by private investors. We have a contract manufacturer and our device consists of proven (medical) certified components. The Leadership team is a mature mix of proven professionals in the industry and are driven to make impact.

CorTec GmbH is a neurotechnology company developing and manufacturing high-performance neural interfaces and Brain-Computer Interface (BCI) systems. Our mission is to restore lost neurological function and enable new treatments for neurological diseases. With a strong foundation in clinical innovation and strategic partnerships, CorTec is shaping the future of neurotherapies.

We are a Munich-based, VC-backed, EIC-Accelerator-awarded deep tech startup with an exceptional team. Our core technology is IP-secured and based on 20 years of cutting-edge R&D at TU Munich and Ebenbuild. Leveraging our digital twin platform technology for respiratory diseases, our AI-enabled medical SaaS product Aerogram lets doctors personalize mechanical ventilation in patients with severe lung complications well & fast. The initial $9b market opportunity in the US, EU & Japan is the beachhead into a $50b market for platform products in chronic disease management and screening. We are raising a Series A to run clearance trials and enter the European and US market.

Improved diagnostic solutions contribute to the development of more precise and personalized medicine and improve the quality of life for patients worldwide. Founded in 2008, Innobiochips provides novel, breakthrough technologies and solutions to improve the accuracy, quality and sustainability of in vitro diagnostic approaches. Today, Innobiochips is a commercial IVD company with a diversified portfolio of innovative technologies and solutions. The company's core assets are its proprietary and patented SirYus™ and Omnys™ technologies, multiplex immunoassay platforms designed for the development of scalable and versatile IVD devices. The most significant recent development is Omnys, the next-generation blood testing solution launched in 2024 and dedicated to Transfusion diagnostic. With its innovative product portfolio and dual business model of direct commercialization and strategic licensing, Innobiochips is well-positioned within the global In Vitro Diagnostics (IVD) market. The company presents a compelling opportunity for investors seeking to participate the improvement of global human health.

Lifespin is transforming diagnostics by combining advanced metabolomics, NMR technology, and AI to deliver fast, scalable, and cost-effective health assessments. From a single blood sample, Lifespin generates a digital metabolomic twin, analyzing 250+ biomarkers to detect early signs of non-communicable diseases (NCDs)—including diabetes, cardiovascular risks, and liver dysfunction—before symptoms emerge. With a proprietary database of over 250,000 profiles and validation from 50+ clinical partners, Lifespin’s cloud-based SaaS platform reduces diagnostic costs by up to 10x and supports both clinical and at-home applications. Strategic alliances—such as with IHH Healthcare—accelerate global adoption. Targeting a $100B+ market, Lifespin is leading the shift from reactive care to proactive, data-driven medicine—empowering earlier intervention and better outcomes in the fight against NCDs.

According to a 2010 EU study, only 5% of people who need mental health support actually receive it — albeit five to 10 years too late. mindcoa.ch was founded in 2017 with the specific aim of alleviating mental health problems through technological support. The focus has always been on the use and development of current IT components in combination with relevant scientific partners such as the Medical University of Vienna. The work of mindcoa.ch has received several awards (e.g., Innovation Award, EIT Health finalist, etc.). Currently, the mindcoa.ch team is working on the implementation of a serious game for coaching in order to provide up-to-date support in all relevant areas of life through prevention and education measures.

PreComb Therapeutics is a Swiss precision-oncology company industrializing Functional Precision Oncology (FPO). Our 3DTwin® platform grows patient-derived 3D micro-tumors from fresh biopsies and measures real-time drug response at scale, delivering data that mirrors in-vivo biology with in-vitro speed, standardization, and reproducibility. The mission: make functional testing routine- de-rsking biopharma R&D today and, medium-term, guiding therapy selection for every solid-tumor patient. Why this matters: genomics alone often fails to predict benefit; most patients are not eligible for targeted therapies and receive trial-and-error treatment that can underperform and add toxicity and cost. PreComb directly measures how an individual patient’s tumor responds to drugs and combinations in a physiologically relevant microenvironment, enabling more confident decision-making across discovery, translation, and development. What we do: 3DTwin treats each sample like a mini clinical trial with automated sample intake, 3D culture, high-content imaging, and ML analytics to test hundreds of conditions per patient. We support target validation, mechanism-agnostic candidate selection, combination design, and transcriptomic readouts of drug-induced expression, with emerging IO assays. Why we win: PreComb uniquely industrializes FPO via automation at scale, real-time readouts, and an operations backbone that reduces variability, cuts turnaround, and increases throughput. Our dual-market strategy (biopharma services now; clinical decision support next) builds durable advantage, reinforced by a diversified IP position, a proprietary response dataset, and strategic partnerships (e.g., University Hospital Zurich for clinical collaboration; Tecan for device manufacturing and co-marketing). A third-party leasing model lowers upfront capex for decentralized adoption; cloud-native analytics enable distributed, standardized testing. Traction & plan: First customer project completed with a repeat engagement; CAR-T proof-of-concept demonstrated; six publications in preparation; capacity expanding toward ~90 screens/month. We are raising Series B to scale commercial delivery, expand our dataset and network, place additional devices at partner sites, and fund clinical feasibility and regulatory readiness on the path to CE-IVD.

EdgeVitals — Contactless Vitals. Anywhere. Instantly. EdgeVitals provides the technology for camera-based vital signs monitoring, enabling telehealth platforms, clinics, and workforce readiness checks to capture accurate vitals in seconds. No extra hardware. No cloud risk. Privacy-first by design.

Glass Medical AI is a tech-bio spin-out from the University of Amsterdam and the Netherlands Cancer Institute, built on five years of academic R&D. The company develops predictive AI technology to transform oncology drug development. Our mission is to accelerate the delivery of effective cancer therapies by enabling smarter, more precise clinical trials. Our proprietary algorithms stratify patients and optimize study design across indications, supporting breakthrough treatments such as checkpoint inhibitors, CAR-T, and TIL therapies. Our vision is simple: deliver the right treatment to the right patient, smarter and faster.

Inn’Pulse is revolutionizing cardiac arrest prevention with a pocket-sized connected defibrillator, as powerful as traditional devices. Guided by an intuitive app, it enables faster, life-saving interventions anywhere.

Neurochlore is a pioneering French start-up dedicated to studying the brain’s fundamental mechanisms in perinatal period. Built on the innovative concepts of Neuroarchaeology and GABAergic polarity, the company has shed light on the crucial role of the excitation/inhibition balance in building a functional brain. This imbalance is now recognized as a central factor in numerous neurodevelopmental disorders—most notably autism—as well as in certain brain pathologies such as tumors. Building on this strong scientific foundation, Neurochlore structures its research and innovation around two strategic axes : Axis 1 – Biomedical Research & AI: Focused on artificial intelligence and computational analysis applied to medicine and biology. This axis focuses on developing tailored data analysis solutions for both structured datasets and complex imaging data (MRI, microscopy, CT scans, etc.), enabling the detection, prediction, and modeling of biological processes. It also advances in-house projects to create new diagnostic support tools, accelerating the path from data to discovery. Axis 2 – Oncological Therapeutics: Dedicated to the development of innovative approaches for complex and treatment-resistant brain tumors. By combining two anticancer molecules and integrating research on the neuronal environment and hyperexcitability that drive tumor progression, this axis explores a paradigm shift in brain cancer therapy, with promising extensions to other pathologies involving disrupted chloride homeostasis. By bringing together fundamental science, technological innovation, and translational medicine, Neurochlore is shaping the future of neuroscience and tomorrow’s therapies. Neurochlore is active participants in the IBEN Project (Institut Ben-Ari d’Innovation), a future high-tech biotech hub in Marseille. Located on the Luminy science campus, the 6,600 m² building—designed by Rudy Ricciotti in partnership with Eiffage Immobilier and Tivoli Capital—is set to open by 2027, hosting laboratories, offices, and collaborative spaces dedicated to cutting-edge biotech and health AI companies.

NovaPump's "PERKAT" plaform (from Jena/ Germany) is the novel percutaneous, self-expanding heart-pump for safe implantations and pulsatile circulation support for acute care patients with clear USP’s (mentioned and cited in leading medical text books and papers, award winning: 1st place at German Medical Award, 1st place at Lothar Spaeth Award from EU Commissioner Guenther Oettinger). So- we are currently rasing our serious round B. Comment: We are former inventors & co-founders of the JenaValve technique, too (the worldwide first technique for selfexpanding TAVI procedures/ to replace the aortic valve percutaneously and wwith a self-expanding NiTi cage; JenaValve was sold to Edwards in 2024 sucessfully. If you want to joyn our investment round possibly (and want to become a part of the word-wide leading cutting-edge technique for acute right heart patients) please get in touch with us (info@novapump.de). Today's mortality rate is for aRHF patients about 50% (30d) so we have the aim & the potential to become a market leader here!

NxNeuro is an innovative medtech company redefining the future of epilepsy care. We are developing groundbreaking medical devices and AI tools to make the diagnosis and surgical treatment of epilepsy safer, more effective, and more accessible — without the need for lifelong implanted devices or daily medication.

Platypus is an AI-driven health platform that detects chronic diseases years before symptoms appear and guides users with personalized, daily habit recommendations to prevent them.

Surgical Reality is a 3D surgery platform that allows doctors to visualize a colored 3D model of the patient within minutes. The 3D visualizations guide surgeons before and during operations, comparable to a Google Maps for surgeons. Surgical Reality is CE/MDR approved, ISO13485, ISO27001 certificied and expecting FDA approval in Q1 2026. 25 leading European hospitals are currently trailing our lung imaging technology. We're fully focussing on converting them to paying hospitals and developing new imaging modalities which expect to be launched Q2 2026. Royal Papworth (UK's leading heart & lung center), Ruhrlandklinik Essen (Germany's #2 lung center) and multiple Dutch, Swiss and Norwegian hospitals are currently implementing our technology.

VUS Genetics is developing a disruptive gene editing/CRISPR platform innovation to efficiently accelerate pre-clinical drug target development and improve patient stratification. Our goal is to build a comprehensive database of genetic biomarkers to drive successful, personalized clinical trials.

YourHeartCheck.com is a pioneering digital health company dedicated to empowering individuals to take control of their heart health through accessible, accurate, and convenient cardiac screening. Targeting the “worried well” population—adults aged 40+ who are generally healthy but conscious of potential heart risks—the company offers direct-to-consumer ECG Holter monitoring and blood pressure analysis services without the need for GP referral. The platform combines advanced medical technology with a seamless online user experience. Customers can order clinically approved monitoring devices delivered to their home, record their heart activity, and return them for expert interpretation. Results are analysed by a team of qualified cardiologists, with easy-to-understand reports delivered securely online. This enables early detection of potential cardiac issues such as arrhythmias and hypertension, supporting timely medical intervention. Founded and led by Dr. Chris Crockford (CEO), YourHeartCheck.com’s leadership team brings deep expertise from healthcare, technology, and commercial sectors. Key team members include Claire Owen (CTO), Martin Peters (CFO), Ben Alexander (CMO), Jeremy Bishop (Chief Commercial Officer), and Dr. Andrew Mitchell (Chief Medical Officer). YourHeartCheck.com’s mission is to remove barriers to early cardiac screening, reduce preventable heart-related emergencies, and promote peace of mind through reliable health insights. The company operates across the UK, EU, USA, and Middle East, adhering to rigorous medical and data protection standards. With first commercial revenues already achieved and growing demand from health-conscious consumers, YourHeartCheck.com is well positioned for international expansion and strategic partnerships. In addition to its consumer services, the company is exploring opportunities in corporate wellness programs, insurance partnerships, and military applications, ensuring its technology delivers benefits across multiple sectors. YourHeartCheck.com – helping you understand your heart, before it needs urgent attention.